30 closest matches · ranked by relevance
Non-Alcoholic Steatohepatitis (NASH)
Primary: SAF Activity Score (SAF-A) Decrease of at Least 2 Points With no Worsening of the CRN Fibrosis Score (CRN-F) — 41; 34; 22; 42 Participants — p==0.061
Nonalcoholic Steatohepatitis (NASH)
Primary: Absolute Change in Hepatic Fat Fraction Based on MRI-PDFF Measurements in LPCN 1144 Treated Subjects Compared to Placebo. — -7.68; -9.17; -1.54 Percentage of liver fat…
Nonalcoholic Steatohepatitis · Nonalcoholic Fatty Liver Disease · Type 2 Diabetes Mellitus
Primary: Liver Histology (Using Kleiner et al Criteria, Hepatology 2005) — 9; 29 Participants
Fatty Liver Disease, Nonalcoholic
Primary: Non-alcoholic Steatohepatitis Score as Determined by Liver Histopathology at 12 Months — 5 units on a scale — p=0.015
Liver Diseases · Blood Disorder · Digestive System Disease
Primary: PAI-1 Level — 151.4; 176.2 ng/mL
Hepatitis
Primary: Number of Patients With Improvement in Liver Histology — 12 participants
Non-Alcoholic Steatohepatitis (NASH)
Primary: Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) — 21…
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Primary: Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis…
NASH - Nonalcoholic Steatohepatitis
Primary: Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3…
Hepatic Cirrhosis · Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48 — 28.2; 24.3; 28.2…
Nonalcoholic Steatohepatitis (NASH) · Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events — 50; 60; 50; 25 percentage of participants
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Primary: Percent Change in Hepatic Fat Fraction by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) From Baseline — -11.31; -27.59; 2.52; -28.68 percent change…
NASH - Nonalcoholic Steatohepatitis
Primary: Main: Absolute Change From Baseline in Hepatic Fat Fraction Assessed by MRI-PDFF at Week 12. — -12.32; -13.44; -14.14; -0.29 Absolute percentage of hepatic fat
NASH - Nonalcoholic Steatohepatitis
Primary: Safety and Tolerability of Treatment — 12; 13; 13; 18 Participants
Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis (NASH)
Primary: Hepatic Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) — 50; 23 participants — p=0.0002
NASH - Nonalcoholic Steatohepatitis
Primary: Number of Participants With Adverse Events for TERN-101 Versus Placebo — 10; 13; 14; 15 Participants
Hepatitis
Primary: Change in the Histological NASH Activity Index at 48 Weeks Compared With Baseline (Number of Participants in Each Change Category) — 9; 11; 5; 1 participants — p=<0.001
Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis
Primary: The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24 — 30.6; 24.0; 26.5; 14.3 Percentage of Participants — p=0.055
Nonalcoholic Fatty Liver · Nonalcoholic Steatohepatitis
Primary: Absolute Change in Intrahepatic Lipid Content, by 1H-MRS — -6.6; 3.6 Mean absolute percentage change
NASH - Nonalcoholic Steatohepatitis
Primary: Patient Incidence of Adverse Events for TERN-201 Versus Placebo — 9; 11; 8 Participants
Steatohepatitis
Primary: Histological Response Defined by Change From Baseline in Standardized Scoring of Liver Biopsies — 18; 18; 20 participants — p=0.57
NASH
Primary: Part 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs) — 6; 4; 7; 7 Participants
NASH - Nonalcoholic Steatohepatitis
Primary: Change in Liver Stiffness on Magnetic Resonance Elastography (MRE) — 0.025; -0.265; 0.105; 0.135 Change in kPA
Nonalcoholic Steatohepatitis (NASH)
Primary: Number of Participants With Treatment-related Adverse Events. — 3 Participants
Fatty Liver
Primary: Normalization or >50% of Serum ALT Levels From Baseline — 7 participants
Non-Alcoholic Steatohepatitis (NASH) · Type2 Diabetes Mellitus
Primary: Change in MRI-Proton Density Fat Fraction (MRI-PDFF) — 21.3; 14.4; -6.9 percentage fat in the liver — p=0.03125
NASH - Nonalcoholic Steatohepatitis
Primary: Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of Fibrosis — 5; 12; 11; 1 Participants…
Diabetes Mellitus, Type 2 · NASH - Nonalcoholic Steatohepatitis
Primary: Number of Treatment-Emergent Adverse Events — 0; 2 Adverse Events
Non-alcoholic Steatohepatitis (NASH)
Primary: Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3)…
Non-alcoholic Steatohepatitis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Possibly or Probably Related to Treatment — 0; 0; 1; 3 participants